약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
Table. 1.
Table. 1.
Table 1
A 2x2 table for disproportionality calculation
Adverse events of interest
All other adverse events
baricitinib (or tocilizumab)
A
B
Comparison group
C
D
Yakhak Hoeji 2022;66:49-57
https://doi.org/10.17480/psk.2022.66.2.49
© 2022 Yakhak Hoeji